The top 25 drugs ranked by nonfederal hospital expenditure in 2023: Bictegravir/emtricitabine/tenofovir/alafenamide — $643,390,000 (18.9% change) Pneumococcal vaccine conjugate — $585,635,000 (29.5% ...

This story is part of a series, “Fighting ‘Forever Chemicals’: Women face pervasive PFAS risks.” Cancer-linked “forever ...

Cullinan plans to exclusively pursue development of its T-cell-engager CLN-978 in autoimmune disorders, beginning as a ...

Researchers at the Indian Institute of Science (IISc) have designed a synthetic compound (antigen) that can latch on to a ...

With chronic renal problems often diagnosed too late, here’s how to stay vigilant and get yourself checked over ...

Lucky for us, salami has two white things to unpack. The first one is mold—but it’s on purpose. Are those powdery splotches ...

The 30-year-old singer was arrested earlier this month after he allegedly threw a chair off the rooftop of a six-story bar in ...

Pancreatic cancer develops when abnormal cells in the pancreas grow uncontrollably, causing symptoms like fatigue, jaundice, ...

It represents the first systemic therapy for pediatric low-grade gliomas harboring BRAF rearrangements, or fusions, according ...

Bengaluru, have developed synthetic (compound) antigens that can boost the production of antibodies that fight against cancer ...

CLN-978 contains two single-chain variable fragments (scFv), one binding with very high affinity to the CD19 target and the other binding to CD3 on T cells, and a single-domain antibody (VHH) binding ...

Positive high-level results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful ...